Lantheus price to free cash flow LNTH

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: 16.8×
10-year median: 17.5×
Against its 10-year history: 44th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.0× to 427×
Peer median: 28.0×

Lantheus' price to free cash flow is 16.8× as of Oct 23, 2026.

That is below its ten-year median of 17.5×, close to the middle of its last ten years.

Over that time it ranged from 7.0× in Apr 2020 to 427× in Jul 2021.

The median for 10 diagnostics and research stocks of a similar size is 28.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	16.8×	10.3×	19.0×
2025	10.7×	7.2×	15.1×
2024	13.8×	11.5×	28.0×
2023	68.4×	19.4×	281×
2022	20.4×	20.2×	127×
2021	66.9×	39.9×	427×
2020	36.3×	7.0×	40.0×
2019	15.7×	15.7×	25.5×
2018	15.1×	14.6×	21.9×
2017	19.0×	7.4×	21.0×
2016	7.7×	6.1×	9.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.

Company	Price to free cash flow
LNTHLantheus	16.8×
BLLNBillionToOne	153×
CAICaris Life Sciences	73.0×
BIOBio-Rad Laboratories	28.0×
VCYTVeracyte	23.2×
CDNACareDx	n/m
RVTYRevvity	31.7×
MEDPMedpace	26.4×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
MTDMettler-Toledo International	38.7×
Peer median	28.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lantheus

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.